Group One Trading’s Ovid Therapeutics OVID Stock Holding History

Group One Trading’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,000	Closed	-$11.1K	–	8239
2026 Q1	$11.1K	Buy	5,000 +500	+11%	+$894	﹤0.01%	6321
2025 Q4	$7.33K	Sell	4,500 -130,000	-97%	-$200K	﹤0.01%	6987
2025 Q3	$175K	Buy	+134,500	New	+$117K	﹤0.01%	4810
2021 Q4	–	Sell	-233,500	Closed	-$785K	–	8682
2021 Q3	$785K	Sell	233,500 -161,400	-41%	-$589K	﹤0.01%	3679
2021 Q2	$1.54M	Sell	394,900 -43,900	-10%	-$173K	﹤0.01%	2913
2021 Q1	$1.76M	Buy	438,800 +417,200	+1,931%	+$1.39M	﹤0.01%	2606
2020 Q4	$50K	Buy	21,600 +20,000	+1,250%	+$93.2K	﹤0.01%	5006
2020 Q3	$9K	Buy	+1,600	New	+$10.7K	﹤0.01%	5464

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Group One Trading's OVID Position: Q2 2026 in Review

Group One Trading increased its Ovid Therapeutics (OVID) stake by 41% in Q2 2026, buying an estimated $14K and bringing the position to 18,663 shares worth $50.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5400.

Group One Trading first reported a position in OVID in Q2 2020 and has held it in 13 quarters since. The position peaked at $669K in Q1 2021. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Group One Trading held 18,663 shares of Ovid Therapeutics worth $50.2K as of Q2 2026.
Group One Trading bought 5,417 Ovid Therapeutics shares in Q2 2026, an estimated $14K.
Ovid Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5400 holding.
Group One Trading first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 13 quarters since.
Group One Trading's Ovid Therapeutics position peaked at $669K in Q1 2021.
130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.